SNDX - Syndax Pharmaceuticals Inc

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 20.29

Open

$ 20.62

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 20.25 - $ 20.66

52 Week Range

$ 11.22 - $ 25.34

Volume

957,497

Average Volume

Market Cap

1.73B

Beta (5Y Monthly)

$ 0.76

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-08-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-08-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	03-01-2022	12-31-2021	10-K
11	11-15-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-11-2021	03-31-2021	10-Q
14	03-12-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-05-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	03-07-2019	12-31-2018	10-K
23	11-05-2018	09-30-2018	10-Q
24	08-08-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-08-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-10-2017	06-30-2017	10-Q
29	05-09-2017	03-31-2017	10-Q
30	03-14-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-15-2016	06-30-2016	10-Q
33	05-16-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Citigroup Maintains Buy on Syndax Pharmace...
05/09/2024 17:52:25

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target fr...

Stifel Maintains Buy on Syndax Pharmaceuti...
05/09/2024 14:05:58

Stifel analyst Bradley Canino maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $39...

HC Wainwright & Co. Reiterates Buy on Synd...
05/09/2024 10:56:10

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

Syndax Pharmaceuticals Q1 2024 GAAP EPS $(...
05/08/2024 11:17:38

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate o...

HC Wainwright & Co. Reiterates Buy on Synd...
04/26/2024 11:37:35

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

$syndax-pharmaceuticals-announced-the-presentation-of-data-from-augment-101-trial-in-pediatric-patients-with-relapsedrefractory-kmt2a-rearranged-acute-myeloid-leukemia-and-acute-lymphoid-leukemia-treated-with-revumenib$

Syndax Pharmaceuticals Announced The Prese...
04/08/2024 11:10:59

Consistent safety and efficacy profiles across adult and pediatric populations – Majority of pediatric patients who achieved...

Live On CNBC, StemPoint Capital CIO Michel...
04/03/2024 16:52:48

HC Wainwright & Co. Reiterates Buy on Synd...
03/28/2024 13:53:10

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

$syndax-disclosed-completion-of-enrollment-in-augment-101-pivotal-trial-cohort-of-patients-with-relapsedrefractory-mnpm1-acute-myeloid-leukemia--expects-topline-data-in-q1-2024$

Syndax Disclosed Completion Of Enrollment ...
03/28/2024 11:03:08

HC Wainwright & Co. Maintains Buy on Synda...
03/27/2024 10:21:33

HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pri...

$syndax-reports-fda-priority-review-of-nda-for-revumenib-for-treatment-of-relapsedrefractory-kmt2ar-acute-leukemia$

Syndax Reports FDA Priority Review Of NDA ...
03/26/2024 20:09:06

– PDUFA action date set for September 26, 2024 –– NDA being reviewed under FDA's RTOR program –

JP Morgan Maintains Overweight on Syndax P...
03/20/2024 15:46:14

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...

HC Wainwright & Co. Reiterates Buy on Synd...
02/28/2024 18:34:15

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

Syndax Pharmaceuticals Expects $600M In Ca...
02/27/2024 23:15:17

For the first quarter of 2024, the Company expects research and development expenses to be $56 to $62 million and total operati...

Syndax Pharmaceuticals: Q4 Earnings Insights
02/27/2024 21:40:33

Syndax Pharmaceuticals Q4 2023 GAAP EPS $(...
02/27/2024 21:37:43

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate...

Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

Earnings Preview: Syndax Pharmaceuticals
02/26/2024 16:01:24

Scotiabank Downgrades Syndax Pharmaceutica...
01/31/2024 14:58:00

Scotiabank analyst George Farmer downgrades Syndax Pharmaceuticals (NASDAQ:SNDX) from Sector Outperform to Sector Perform an...

HC Wainwright & Co. Reiterates Buy on Synd...
01/02/2024 17:07:26

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...